Search

Your search keyword '"Buchholz E"' showing total 239 results
Start Over Author "Buchholz E"

Refine your results

239 results on '"Buchholz E"'

18. Schrifttumsberichte

Author

Runkel, R., Bavendamm, W., Schmidt, H., Weck, J., Keylwerth, R., Kollmann, F., Buchholz, E., Buchholz, E., Sandermann, W., Sandermann, W., and Schmidt, H.

Published
1951
Full Text
View/download PDF

19. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Author

Ardizzoni, A., Tjan-Heijnen, V.C., Postmus, P.E., Buchholz, E., Biesma, B., Karnicka-Mlodkowska, H., Dziadziuszko, R., Burghouts, J.T.M., Meerbeeck, J.P. van, Gans, S., Legrand, C., Debruyne, C., Giaccone, G., and Manegold, C.

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Cyclophosphamide, medicine.medical_treatment, Gastroenterology, Small-cell carcinoma, Statistics, Nonparametric, Experimental diagnostics and therapy of malignancies, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Humans, Prospective Studies, Carcinoma, Small Cell, Lung cancer, Survival rate, Etoposide, Aged, Proportional Hazards Models, Chemotherapy, Dose-Response Relationship, Drug, Cumulative dose, business.industry, Leukopenia, Antibiotic Prophylaxis, Middle Aged, medicine.disease, Surgery, Granulocyte colony-stimulating factor, Europe, Survival Rate, Treatment Outcome, Oncology, Doxorubicin, Female, business, medicine.drug
Abstract

PURPOSE: To assess the impact on survival of increasing dose-intensity (DI) of cyclophosphamide, doxorubicin, and etoposide (CDE) in small-cell lung cancer (SCLC). PATIENTS AND METHODS: Previously untreated SCLC patients were randomized to standard CDE (cyclophosphamide 1,000 mg/m2 and doxorubicin 45 mg/m2 on day 1, and etoposide 100 mg/m2 on days 1 to 3 every 3 weeks, for five cycles) or intensified CDE (cyclophosphamide 1,250 mg/m2 and doxorubicin 55 mg/m2 on day 1, and etoposide 125 mg/m2 on days 1 to 3 with granulocyte colony-stimulating factor [G-CSF] 5 μg/kg/d on days 4 to 13 every 2 weeks, for four cycles). Projected cumulative dose was almost identical on the two arms, whereas projected DI was nearly 90% higher on the intensified arm. Two hundred forty-four patients were enrolled. The first 163 patients were also randomized (2 × 2 factorial design) to prophylactic antibiotics or placebo to assess their impact on preventing febrile leukopenia (FL). This report focuses on chemotherapy DI results. RESULTS: With a median follow-up of 54 months, 216 deaths have occurred. Actually delivered DI on the intensified arm was 70% higher than on the standard arm. Intensified CDE was associated with more grade 4 leukopenia (79% v 50%), grade 4 thrombocytopenia (44% v 11%), anorexia, nausea, and mucositis. FL and number of toxic deaths were similar on the two arms. The objective response rate was 79% for the standard arm and 84% for the intensified arm (P = .315). Median survival was 54 weeks and 52 weeks, and the 2-year survival rates were 15% and 18%, respectively (P = .885). CONCLUSION: A 70% increase of CDE actual DI does not translate into an improved outcome in SCLC patients.

Published
2002

20. Schrifttumsberichte

Author

Mayer-Wegelin, H., Rügge, K., Bavendamm, W., Keylwerth, R., Schmidt, H., Fickler, H. H., Lünzmann, K., Kast, W., Stockmann, H., Schulz, F., Kübler, H., Buchholz, E., and Kübler, H.

Published
1952
Full Text
View/download PDF

21. Schrifttumsberichte

Author

Buchholz, E., Keylwerth, R., Rügge, K., Schulz, F., Mayer-Wegelin, H., Bavendamm, W., Schmidt, H., Francke-Gresmann, H., Runkel, R., Witt, H., Sandermann, W., Kollmann, F., Brüning, H., and Kienzle, A.

Published
1951
Full Text
View/download PDF

23. Einzelbesprechungen

Author

Brandt, K., Stobbe, A., Buchholz, E. H., Weissel, E., Minet, P., Montaner, A., Borchardt, K., Bachmann, H. B., Nowotny, Th., Vlcek, J., Andreae, C. -A., Streissler, M., Nußbaumer, A., Pütz, Th., Rothschild, K. W., Schadlbauer, F. G., Garzón, Carlos Uribe, and Firnberg, H.

Published
1964
Full Text
View/download PDF

24. Schrifttumsberichte

Author

Schulz, F., Bavendamm, W., Mayer-Wegelin, H., Lünzmann, K., Sandermann, W., Witt, H., Kübler, H., Buchholz, E., Keylwerth, R., and Matz, H.

Published
1952
Full Text
View/download PDF

27. Schrifttumsberichte

Author

Keylwerth, R., Runkel, R., Sandermann, W., Buchholz, E., Mayer-Wegelin, H., Weck, J., Kienzle, A., Schulz, F., Kollmann, F., and Schmidt, H.

Published
1951
Full Text
View/download PDF

30. Schrifttumsberichte

Author

Keylwerth, R., Bavendamm, W., Schulz, F., Kübler, H., Reichenstein, E., Runkel, R., Schmidt, H., Lünzmann, K., Mayer-Wegelin, H., Kast, W., Witt, H., Buchholz, E., Kollmann, F., Stockmann, H., Plath, E., Rügge, K., Brüning, H., and Seitz, H.

Published
1952
Full Text
View/download PDF

43. 827 A phase II randomized study comparing docetaxel/clsplatin induction therapy followed by thoracic radiotherapy with or without weekly docetaxel in unresectable stage IIIA–IIIB non-small cell lung cancer

Author

Manegold, C., primary, Debus, J., additional, Buchholz, E., additional, Scagliotti, G.V., additional, Ricardi, U., additional, Cardenal, F., additional, Mattson, K., additional, Ramlau, R., additional, Szczesna, A., additional, van Zandwijk, N., additional, Price, A., additional, and Morel, A., additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results